Puma Biotechnology (PBYI) Stock Price, News & Analysis

-0.04 (-0.77%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
293,866 shs
Average Volume
562,042 shs
Market Capitalization
$247.32 million
P/E Ratio
Dividend Yield
Price Target

Puma Biotechnology MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
36.5% Upside
$7.00 Price Target
Short Interest
9.54% of Float Sold Short
Dividend Strength
News Sentiment
0.53mentions of Puma Biotechnology in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.84 out of 5 stars

Medical Sector

393rd out of 910 stocks

Pharmaceutical Preparations Industry

178th out of 426 stocks

PBYI stock logo

About Puma Biotechnology Stock (NASDAQ:PBYI)

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

PBYI Stock Price History

PBYI Stock News Headlines

Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Puma Biotechnology Inc.
Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B
Puma Biotechnology Inc PBYI
See More Headlines
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
$21.59 million
Pretax Margin


Sales & Book Value

Annual Sales
$235.60 million
Cash Flow
$0.73 per share
Book Value
$1.12 per share


Free Float
Market Cap
$253.10 million
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

PBYI Stock Analysis - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings
or view top-rated stocks.

What is Puma Biotechnology's stock price target for 2024?

1 Wall Street analysts have issued 12 month price objectives for Puma Biotechnology's shares. Their PBYI share price targets range from $7.00 to $7.00. On average, they predict the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 36.5% from the stock's current price.
View analysts price targets for PBYI
or view top-rated stocks among Wall Street analysts.

How have PBYI shares performed in 2024?

Puma Biotechnology's stock was trading at $4.33 at the beginning of 2024. Since then, PBYI stock has increased by 18.5% and is now trading at $5.13.
View the best growth stocks for 2024 here

When is Puma Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PBYI earnings forecast

How can I listen to Puma Biotechnology's earnings call?

Puma Biotechnology will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) posted its earnings results on Thursday, February, 29th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by $0.07. The biopharmaceutical company had revenue of $72.20 million for the quarter, compared to analyst estimates of $73.22 million. Puma Biotechnology had a net margin of 9.16% and a trailing twelve-month return on equity of 58.21%.

What guidance has Puma Biotechnology issued on next quarter's earnings?

Puma Biotechnology updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $214.0 million-$225.0 million, compared to the consensus revenue estimate of $244.7 million.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PBYI) was last updated on 4/23/2024 by Staff

From Our Partners